Picture of Axim Biotechnologies logo

AXIM Axim Biotechnologies Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m+20.51%
3m+13.59%
6m+96.84%
1yr+196.38%
Volume Change (%)
10d/3m-38.13%
Price vs... (%)
52w High-58.96%
50d MA-19.09%
200d MA+35.39%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-3579%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Axim Biotechnologies EPS forecast chart

Profile Summary

Axim Biotechnologies, Inc. develops and commercializes rapid, point-of-care diagnostic tests focused on ocular and systemic health. The Company's TearScan platform enables clinicians to quantify tear biomarkers with laboratory-grade accuracy in office settings, enhancing diagnostic confidence and treatment outcomes. The Company's product portfolio falls under the Eye Health sector and consists of the two FDA cleared 510(k) tests for dry eye disease (DED) and allergic conjunctivitis, both testing tears for these diseases. It has also internally developed an immunoassay for a potential third product which would measure MMP-9 in tears. MMP-9 is a biomarker for ocular surface inflammation and is an additional diagnostic tool for DED and other eye diseases. Its ophthalmological diagnostic tests include Ocular Immunoglobulin E (IgE) Test and Lactoferrin Test. IgE is a biomarker for allergic conjunctivitis, which often mimics dry eye disease or co-exists with dry eye disease.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    June 30th, 2024
    Incorporated
    November 18th, 2010
    Public Since
    April 9th, 2013
    No. of Shareholders
    156
    No. of Employees
    6
    Sector
    Healthcare Equipment & Supplies
    Industry
    Healthcare
    Exchange
    us flag iconPink Sheets on Nasdaq
    Shares in Issue
    332,956,626

    AXIM Share Price Performance

    Upcoming Events for AXIM

    Q4 2025 Axim Biotechnologies Inc Earnings Release

    Similar to AXIM

    Picture of Aamaxan Transport logo

    Aamaxan Transport

    us flag iconPink Sheets on Nasdaq

    Picture of ACCUSTEM SCIENCES logo

    ACCUSTEM SCIENCES

    us flag iconPink Sheets on Nasdaq

    Picture of Acutus Medical logo

    Acutus Medical

    us flag iconPink Sheets on Nasdaq

    Picture of ADM Tronics Unlimited logo

    ADM Tronics Unlimited

    us flag iconPink Sheets on Nasdaq

    FAQ